Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M37,966Revenue $M1,551Net Margin (%)23.3Z-Score31.7
Enterprise Value $M36,341EPS $1.3Operating Margin %38.7F-Score8
P/E(ttm))79.6Cash Flow Per Share $0.8Pre-tax Margin (%)38.8Higher ROA y-yY
Price/Book12.210-y EBITDA Growth Rate %0Quick Ratio4.8Cash flow > EarningsY
Price/Sales18.65-y EBITDA Growth Rate %52.4Current Ratio5.1Lower Leverage y-yY
Price/Cash Flow115y-y EBITDA Growth Rate %59.3ROA % (ttm)14.1Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)18.0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M198ROI % (ttm)16.0Gross Margin Increase y-yY

Gurus Latest Trades with ALXN

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ALXNAndreas Halvorsen 2014-06-30 Add0.12%$139.61 - $170.2
($157.93)
$ 190.4921%Add 9.23%2,006,092
ALXNJoel Greenblatt 2014-06-30 Add0.02%$139.61 - $170.2
($157.93)
$ 190.4921%Add 240.11%17,094
ALXNRay Dalio 2014-06-30 Reduce-0.03%$139.61 - $170.2
($157.93)
$ 190.4921%Reduce -47.72%26,332
ALXNJohn Burbank 2014-06-30 Sold Out -0.01%$139.61 - $170.2
($157.93)
$ 190.4921%Sold Out0
ALXNRay Dalio 2014-03-31 Buy 0.06%$129.82 - $183.89
($158.27)
$ 190.4920%New holding, 50371 sh.50,371
ALXNJoel Greenblatt 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 190.4920%New holding, 5026 sh.5,026
ALXNJohn Burbank 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 190.4920%New holding, 1318 sh.1,318
ALXNRon Baron 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 190.4920%New holding, 10218 sh.10,218
ALXNFrank Sands 2014-03-31 Reduce-0.74%$129.82 - $183.89
($158.27)
$ 190.4920%Reduce -28.52%5,268,418
ALXNAndreas Halvorsen 2014-03-31 Reduce-0.65%$129.82 - $183.89
($158.27)
$ 190.4920%Reduce -36.16%1,836,658
ALXNAndreas Halvorsen 2013-12-31 Reduce-0.37%$105.48 - $132.91
($119.84)
$ 190.4959%Reduce -16.72%2,877,008
ALXNAndreas Halvorsen 2013-09-30 Reduce-1.06%$94.34 - $117.28
($109.83)
$ 190.4973%Reduce -37.7%3,454,640
ALXNFrank Sands 2013-09-30 Reduce-0.27%$94.34 - $117.28
($109.83)
$ 190.4973%Reduce -10.5%7,540,405
ALXNAndreas Halvorsen 2013-06-30 Reduce-2.15%$87.99 - $107.86
($96.37)
$ 190.4998%Reduce -41.4%5,544,949
ALXNAndreas Halvorsen 2013-03-31 Add2.99%$83.39 - $102.57
($93.13)
$ 190.49104%Add 135.72%9,462,442
ALXNFrank Sands 2013-03-31 Add0.11%$83.39 - $102.57
($93.13)
$ 190.49104%Add 4.23%8,420,336
ALXNJoel Greenblatt 2013-03-31 Sold Out -0.07%$83.39 - $102.57
($93.13)
$ 190.49104%Sold Out0
ALXNAndreas Halvorsen 2012-12-31 Buy 2.6%$87.97 - $118.15
($98.27)
$ 190.4994%New holding, 4014242 sh.4,014,242
ALXNJoel Greenblatt 2012-12-31 Buy 0.07%$87.97 - $118.15
($98.27)
$ 190.4994%New holding, 12977 sh.12,977
ALXNFrank Sands 2012-06-30 Add0.27%$83.74 - $98.82
($91.04)
$ 190.49109%Add 6.43%9,739,804
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ALXN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ALXN Joel Greenblatt 2014-06-3017,0940.010.03+240.11%
ALXN Andreas Halvorsen 2014-06-302,006,0921.011.4+9.23%
ALXN Frank Sands 2014-06-305,279,7822.672.1+0.22%
ALXN Ron Baron 2014-06-3010,1450.010.01-0.71%
ALXN Ray Dalio 2014-06-3026,3320.010.03-47.72%
ALXN John Burbank 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


ALXN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
SQUINTO STEPHEN PEVP, Chief Global Ops. Officer 2014-10-27Sell5,910$188.581.01view
Moriarty John BSVP & General Counsel 2014-10-27Sell10,000$189.490.53view
Moriarty John BSVP & General Counsel 2014-10-06Sell10,000$1796.42view
SQUINTO STEPHEN PEVP, Chief Global Ops. Officer 2014-10-03Sell10,025$172.4110.49view
BELL LEONARDCEO 2014-09-26Sell60,000$165.1215.36view
SQUINTO STEPHEN PEVP, Chief Global Ops. Officer 2014-09-24Sell76$159.519.43view
BELL LEONARDCEO 2014-09-18Sell44,435$160.618.61view
BELL LEONARDCEO 2014-09-10Sell12,199$165.3815.18view
BELL LEONARDCEO 2014-09-08Sell197,801$165.3215.23view
Carmichael ClareSVP, Chief HR Officer 2014-09-02Sell304$169.4612.41view

Press Releases about ALXN :

    Quarterly/Annual Reports about ALXN:

    News about ALXN:

    Articles On GuruFocus.com
    CEO of Alexion Pharmaceuticals Sells Company Stock Sep 29 2014 
    Alexion CEO Receives Nearly $17 Million for Sale of Company Stock Aug 14 2014 
    Weekly CFO Sells Highlight: Facebook Inc., Cardinal Health Inc., Alexion Pharmaceuticals Inc., Therm Feb 10 2014 
    Weekly Insider Sells Highlight: EA, ALXN, AAL, TMO Feb 09 2014 
    You Can No Longer Ignore Biotech Feb 07 2014 
    Six High-Impact Sells - Viking Global Investors Aug 26 2013 
    CEO of Alexion Pharmaceuticals Inc. Leonard Bell Sold 140,000 Shares Aug 19 2013 
    Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 
    fv 107 Apr 01 2013 
    Weekly Top Insider Sells: GOOG, KSS, ALXN, and QCOM Sep 03 2012 


    More From Other Websites
    Biotech Stock Roundup: Beat & Raise Quarter for Amgen, Celgene, Alexion, Biogen Oct 29 2014
    Top Holdings Of Top Health Care Funds: Alexion, Gilead, Celgene Oct 28 2014
    Four Biotechs Lead Health Care Stocks In Big Cap 20 Oct 27 2014
    How The Moving Averages Help Guide Your Buying And Selling Oct 27 2014
    Alexion Launches Every Day with HPP™ Campaign in Support of Hypophosphatasia (HPP) Awareness Week Oct 27 2014
    IBD 50 Stocks Regain Buy Points Oct 24 2014
    ALEXION PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Oct 24 2014
    Alexion Pharmaceuticals (ALXN) Earnings Report: Q3 2014 Conference Call Transcript Oct 24 2014
    Celgene, Alexion Earnings Top Views, Send Stocks Flying Oct 23 2014
    Researchers to Present Data on Soliris® (eculizumab) as a Treatment for Patients with aHUS at ASN... Oct 23 2014
    ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Oct 23 2014
    Major Indexes Close Higher; Lannett Breaks Out Oct 23 2014
    Researchers to Present Data on Soliris® (eculizumab) as a Treatment for Patients with aHUS at ASN... Oct 23 2014
    Alexion Pharmaceuticals: Nice Earnings, Too Expensive? Oct 23 2014
    Alexion Beats on Earnings & Revenues in Q3, Guides Up Oct 23 2014
    Stocks Jump To Early Gains; Lannett, Alexion Break Out Oct 23 2014
    Alexion Reports Third Quarter 2014 Results Oct 23 2014
    Alexion Pharma quarterly adj profit beats, raises forecast again Oct 23 2014
    Q3 2014 Alexion Pharmaceuticals Inc Earnings Release - Before Market Open Oct 23 2014
    Alexion tops Street 3Q forecasts Oct 23 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK